[ Syntimmune raises $50M in Series B ]

Syntimmune has raised $50 million  in Series B funding.

Founded in 2013, Syntimmune  is a biotechnology company that focuses on FcRn biology for the treatment of IgG-mediated autoimmune diseases.

Thenew financing  will further advance Syntimmune’s clinical development program, which includes two ongoing Phase 1b/2a clinical trials of the company’s lead drug candidate, SYNT001, in pemphigus and warm autoimmune hemolytic anemia, support further preclinical development of SYNT002, as well as additional research activities.

Funding  Series B
Founded  2013
Country  USA
City  New York, NY
Founder / CEO  David de Graaf
Deal Size  $50M
Investors  Partners Innovation Fund
 Apple Tree Partners
 Baxalta Ventures
Previous Investors  same as above